Development of Recombinant Erythropoietin and Erythropoietin Analogs

Textbook of Nephro-Endocrinology

Volumn , Issue , 2009, Pages 35-48

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882499498     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373870-7.00004-1     Document Type: Chapter

References (108)

1. Acharya V.N., Sinha D.K., Almeida A.F., Pathare A.V. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis. J Assoc Physicians India 1995, 43:539-542.
2. Agarwal A.K., Silver M.R., Reed J.E., et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 2006, 260:577-585.
3. Barril, G., Montenegro, J., Ronco, C. et al. (2005). Aranesp (darbepoetin alfa) administered every 2 weeks (Q2W) effectively maintains haemoglobin in patients receiving peritoneal dialysis: results of a pooled analysis of eight European studies. Paper presented at 42nd ERA-EDTA Congress, Istanbul, Turkey.
4. Besarab A., Kline Bolton W., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
5. Besarab A., Reyes C.M., Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002, 40:439-446.
6. Besarab, A., Bansal, V., Fishbane, S. et al. on behalf of the BA16285 study group. (2004). Intravenous CERA (Continuous Erythropoietin Receptor activator) administered once weekly or once every 2 weeks maintains haemoglobin levels in haemodialysis patients with chronic renal anaemia. Abstract Book of the XLI Congress of the ERA-EDTA 230: (Abstract M047).
7. Besarab, A., Zeig, S., Geronemus, R. et al. (2007). Hematide, a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated with epoetin alfa (EPO). Natl Kidney Found Clin Meet 2007, Abs 24.
8. Bock, A; EFIXNES Study Investigators. (2005). Conversion from weekly epoetin to bi-weekly darbepoetin-α maintains hemoglobin and permits dose reductions at higher doses. Results from a prospective study. Paper presented at 42nd ERA-EDTA Congress, Istanbul, Turkey.
9. Boven K., Stryker S., Knight J., et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005, 67:2346-2353.
10. Bren A., Kandus A., Varl J., Buturovic J., Ponikvar R., Kveder R. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study. Artif Organs 2002, 26:91-97.
11. Bugelski P., Nesspor B.T., Spinka-Doms T., et al. Pharmacokinetics and pharmacodynamics of CTNO528, a novel erythropoiesis receptor agonist in normal & anemic rats. Blood 2005, 106:146b.
12. Canaud, B., Braun, J., Locatelli, F. et al. (2006). Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin levels in patients with chronic kidney disease on dialysis [abstract no SP425]. Nephrol Dial Transplant21: iv 157.
13. Capon D.J., Chamow S.M., Mordenti J., et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989, 337:525-531.
14. Carnot P., Deflandre C.L. Sur l'activite hemopoietique du serum au cours de la regeneration du sang. C R Seances Acad Sci. 1906, 143:384-386.
15. Casadevall N., Nataf J., Viron B., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475.
16. Chen S.Y., Cressman S., Mao F., Shao H., Low D.W., Beilan H.S. Synthetic erythropoietic proteins: tuning biological performance by site-specific polymer attachment. Chem Biol 2005, 12:371-383.
17. Coscarella A., Liddi R., Bach S., et al. Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys. Mol Biotechnol 1998, 10:115-122.
18. Coscarella A., Liddi R., Di Loreto M., et al. The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine 1998, 10:964-969.
19. Dalle B., Henri A., Rouyer-Fessard P., Bettan M., Scherman D., Beuzard Y. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 2001, 97:3776-3782.
20. de Francisco A.L., Sulowicz W., Dougherty F.C. Subcutaneous CERA (Continuous Erythropoietin Receptor Activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: an exploratory multiple-dose study. J Am Soc Nephrol 2003, 14:27A-28A. (Abstract SA-FC124).
21. Disney, A., de Jersey, P., Kirkland, G. et al. (2005). Aranesp (darbepoetin alfa) administered once monthly (QM) maintains hemoglobin (Hb) levels in chronic kidney disease (CKD) patients. Paper presented at 42nd ERA-EDTA Congress, Istanbul, Turkey.
22. Dougherty F.C., Beyer U. Safety and tolerability profile of Continuous Erythropoietin Receptor Activator (CERA) with extended dosing intervals in patients with chronic kidney disease on dialysis. Nephrology 2005, 10:A313. (Abstract W-PO40130).
23. Dougherty F.C., Reigner B., Jordan P., Pannier A. CERA (Continuous Erythropoietin Receptor Activator): Dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies. J Clin Oncol 2004, 22(Suppl 15):14S. (Abstract 6692).
24. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 335:2071-2084.
25. Dumont J.A., Bitonti A.J., Clark D., Evans S., Pickford M., Newman S.P. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 2005, 18:294-303.
26. Edmunds M.E., Walls J., Tucker B., et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989, 4:1065-1069.
27. Egrie J.C., Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001, 84:3-10.
28. Egrie J.C., Grant J.R., Gillies D.K., Aoki K.H., Strickland T.W. The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 1993, 10:263.
29. Elliott S., Lorenzini T., Asher S., Aoki K., Brankow D., Buck L. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003, 21:414-421.
30. Erslev A. Humoral regulation of red cell production. Blood 1953, 8:349-357.
31. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987, 316:73-78.
32. Fan Q., Leuther K.K., Holmes C.P., Fong K.L., Zhang J., Velkovska S. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006, 34:1303-1311.
33. Fishbane S., Tare N., Pill J., Haselbeck A. Preclinical pharmacodynamics and pharmacokinetics of CERA (Continuous Erythropoietin Receptor Activator), an innovative erythropoietic agent for anemia management in patients with kidney disease. J Am Soc Nephrol 2003, 14:27A. (Abstract SA-FC 123).
34. Franson K.L., Burggraaf, Bouman-Trio E.A., et al. A phase I, single and fractionated, ascending dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietic mimetic antibody fusion protein, CTNO528 in healthy male subjects. Blood 2005, 106:146b.
35. Gross A.W., Lodish H.F. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006, 281:2024-2032.
36. Halstenson C.E., Macres M., Katz S.A., et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991, 50:702-712.
37. Haselbeck A., Bailon P., Pahlke W., et al. The discovery and characterization of CERA, an innovative agent for the treatment of anemia. Blood 2002, 100:227A. (Abstract 857).
38. Hiramatsu, M., Kubota, J., Akizawa, T., Koshikawa, S., and the KRN 321 Study Group. (2005). Intravenous administration of KRN321 (darbepoetin alfa) once every 4 weeks improves and maintains haemoglobin concentrations in peritoneal dialysis patients. Paper presented at 42nd ERA-EDTA Congress, Istanbul, Turkey.
39. Jelkmann W. Recombinant EPO production - points the nephrologist should know. Nephrol Dial Transplant 2007, 22:2749-2753.
40. Johnson D.W., Pollock C.A., Macdougall I.C. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007, 12:321-330.
41. Kaufman J.S., Reda D.J., Fye C.L., et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis patients. N Engl J Med 1998, 339:578-583.
42. Keown P.A. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. Contrib Nephrol 1991, 88:81-86.
43. Klinger M., Arias M., Vargemezis V., et al. Efficacy of intravenous methoxy polyethylene-glycol epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007, 50:989-1000.
44. Kwan J.T., Pratt R.D. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in pre-dialysis chronic kidney disease patients. Curr Med Res Opin 2007, 23:307-311.
45. Lai P.H., Everett R., Wang F.F., Arakawa T., Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem 1986, 261:3116-3121.
46. Lee D.E., Son W., Ha B.J., Oh M.S., Yoo O.J. The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem Biophys Res Commun 2006, 339:380-385.
47. Levin N.W., Fishbane S., Canedo F.V., et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007, 370:1415-1421.
48. Lin F.K., Suggs S., Lin C.H. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985, 82:7580-7584.
49. Ling B., Walczyk M., Agarwal A., Carroll W., Liu W., Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005, 63:327-334.
50. Livnah O., Stura E.A., Johnson D.L., Middleton S.A., Mulcahy L.S., Wrighton N.C. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996, 273:464-471.
51. Locatelli F., Canaud B., Giacardy F., Martin-Malo A., Baker N., Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003, 18:362-369.
52. Locatelli F., Villa G., Arias M., et al. CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks. J Am Soc Nephrol 2004, 15:543A. on behalf of the BA16286 study group, (Abstract SU-PO051).
53. Locatelli, F., Villa, G., Backs, W., and Pino, M.D. (2005). A phase 3 multicentre, randomised, double-blind, non-inferiority trial to evaluate the efficacy of Aranesp (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp once weekly (QW) in patients on haemodialysis. Paper presented at 42nd ERA-EDTA Congress, Istanbul, Turkey.
54. Macdougall I.C. C.E.R.A. (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005, 4:436-440.
55. Macdougall I.C., Lewis N.P., Saunders M.J., et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990, 335:489-493.
56. Macdougall I.C., Roberts D.E., Coles G.A., Williams J.D. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clinical Pharmacokinetics 1991, 20:99-113.
57. Macdougall I.C., Gray S.J., Elston O., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999, 10:2392-2395.
58. Macdougall I.C., Matcham J., Gray S.J. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003, 18:576-581.
59. Macdougall I.C., Bailon P., Tare N., et al. CERA (Continuous Erythropoietin Receptor Activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol 2003, 14:769A. (Abstract SU-PO1063).
60. Macdougall I.C., Robson R., Opatrna S., et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:1211-1215.
61. Macdougall, I.C., Tucker, B., Yaqoob, M. et al. (2006b). Hematide, a synthetic peptide-based erythropoiesis stimulating agent, achieves correction of anemia and maintains Hb in patients with CKD not on dialysis. Ann Meet Am Soc Nephrol 39, Abs F-FC079.
62. Macdougall I.C., Padhi D., Jang G. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 2007, 22(Suppl. 4):iv2-iv9.
63. Macdougall I.C., Casadevall N., Froissart M., et al. Treatment of erythropoietin antibody-mediated pure red cell aplasia with a novel synthetic peptide-based erythropoietin receptor agonist. Ann Meet Am Soc Nephrol 2007, 40. Abs SU-FC061.
64. Macdougall I.C. Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin J Am Soc Nephrol 2008, 3:200-207.
65. Macdougall I.C., Walker R., Provenzano R., et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008, 3:337-347.
66. Maitani Y., Moriya H., Shimoda N., Takayama K., Nagai T. Distribution characteristics of entrapped recombinant human erythropoietin in liposomes and its intestinal absorption in rats. Int J Pharm 1999, 185:13-22.
67. Mann, J., Kessler, M., Villa, G. et al. (2005). Darbepoetin alfa (DA) every 2 weeks (Q2W) is effective in dialysis patients (pts) on high prior weekly (QW) doses of rHuEPO, a subanalysis of combined data from 8 prospective multicenter studies. Paper presented at ASN 38th Annual Renal Week Meeting, Philadelphia.
68. Mann J., Kessler M., Villa G., et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol 2007, 67:140-148.
69. Martin K.J. Epoetin delta in the management of renal anaemia: results of a 6-month study. Nephrol Dial Transplant 2007, 22:3052-3054. on behalf of the Epoetin Delta 3001 Study Group.
70. Mayer G., Thum J., Cada E.M., et al. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988, 34:525-528.
71. Mitragotri S., Blankschtein D., Langer R. Ultrasound-mediated transdermal protein delivery. Science 1995, 269:850-853.
72. Miyake T., Kung C.K., Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977, 252:5558-5564.
73. National Kidney Foundation KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease - 2007 update of hemoglobin target. Am J Kidney Dis 2007, 50:471-530.
74. Nissenson A.R., Swan S.K., Lindberg J.S., et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002, 40:110-118.
75. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure (1997). National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis30 (4 Suppl 3): S192-240.
76. Padhi, D., and Jang, G. (2005). Pharmacokinetics (PK) of Aranesp (darbepoetin alfa) in patients with chronic kidney disease (CKD) (Abstract MP 165). Paper presented at 42nd ERA-EDTA Congress, Istanbul, Turkey.
77. Padhi D., Ni L., Cooke B., Marino R., Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006, 45:503-510.
78. Pérez-Oliva J.F., Casanova-González M., García-García I., et al. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study. BMC Nephrology 2005, 6:1-11. the Bioequivalence Study of Erythropoietin Group.
79. Phrommintikul A., Haas S.J., Elsik M., et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381-388.
80. Pötgens A., Haberl U., Rybka A., et al. An optimized supravalent EPO mimetic peptide with unprecedented efficacy. Ann Hematol 2006, 85:643.
81. Provenzano R., Besarab A., Macdougall I.C., et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007, 67:306-317. and BA 16528 Study Investigators.
82. Qureshi S.A., Kim R.M., Konteatis Z., Biazzo D.E., Motamedi H., Rodrigues R. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 1999, 96:12156-12161.
83. Rossert J., Eckardt K.-U. Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant 2005, 20:1025-1028.
84. Sarac, E., Veres, Z., Tallam, S., Barton, D., and Gemmel, D. (2004). Hemoglobin responses following de novo darbepoetin alfa (ARANESP) vs epoetin alfa (PROCRIT) administration in anemic chronic kidney disease (CKD) patients. Paper presented at ASN 37th Renal Week Meeting, St Louis.
85. Schellekens H. The first biosimilar epoetin: but how similar is it?. Clin J Am Soc Nephrol 2008, 3:174-178.
86. Sikole A., Spasovski G., Zafirov D., Polenakovic M. Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin Nephrol 2002, 57:237-245.
87. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 335:2085-2098.
88. Skibeli V., Nissen-Lie G., Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001, 98:3626-3634.
89. Spinowitz B.S., Pratt R.D. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 2006, 22:2507-2513.
90. Spinowitz B., Coyne D.W., Lok C.E., et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrol 2008, 28:280-289.
91. Stead R.B., Lambert J., Wessels D., Iwashita J.S., Leuther K.K., Woodburn K.W. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006, 108:1830-1834.
92. Sulowicz W., Locatelli F., Ryckelynck J.-P., et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007, 2:637-646.
93. Suranyi M.G., Lindberg J.S., Navarro J., Elias C., Brenner R.M., Walker R. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003, 23:106-111.
94. Sytkowski A.J., Lunn E.D., Risinger M.A., Davis K.L. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 1999, 274:24773-24778.
95. Tangvoranuntakul P., Gagneux P., Diaz S., Bardor M., Varki N., Varki A. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 2003, 100:12045-12050.
96. Teruel J.L., Pascual J., Jiménez M., et al. Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin. Nephron 1991, 58:135-137.
97. The Court Service - Court of Appeal - Civil Judgement. (2002). In TKT's technology, those cells were designated as R223 cells. Neutral Citation Number: EWCA Civ. 1096. http://www.hmcourtsservice.gov.uk/judgmentsfiles/j1329/Kirin_v_Hoechst.h tm.
98. Toto R.D., Pichette V., Navarro J., et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004, 24:453-460.
99. Tsubakihara, Y., Hiramatsu, M., Iino, Y., Akizawa, T., Koshikawa, S., and the KRN321 Study Group. (2004). The pharmacokinetics of KRN321 (darbepoetin alfa) after subcutaneous (SC) administration: a comparison between peritoneal dialysis and predialysis chronic renal failure (CRF) patients in Japan. Paper presented at 41st ERA-EDTA Congress, Lisbon, Portugal.
100. van Buren, M., van Manen, J.G., Bakker-de Bruin, Y., Boeschoten, E.W. on behalf of the Aranesp registry group (2005). Feasibility to increase the dosing interval of darbepoetin alfa (Aranesp®) to once monthly (QM) in patients with chronic renal insufficiency (CRI). Paper presented at 42nd ERA-EDTA Congress, Istanbul, Turkey.
101. Vanrenterghem Y., Barany P., Mann J.F., et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002, 62:2167-2175.
102. Venkatesan N., Yoshimitsu J., Ohashi Y., et al. Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs. Int J Pharm 2006, 310:46-52.
103. Way J.C., Lauder S., Brunkhorst B., Kong S.M., Qi A., Webster G. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng Des Sel 2005, 18:111-118.
104. Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., Cotes P.M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986, ii:1175-1178.
105. Woodburn, K., Leuther, K., Holmes, C. et al. (2007a). Renal excretion is the primary route of elimination for the erythropoiesis stimulating agent Hematide as assessed by quantitative whole-body autoradioluminography in Sprague Dawley rats. Nephrol Dial Transplant22: (Suppl 6): Abs SaP333.
106. Woodburn K.W., Fan Q., Winslow S., et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007, 35:1201-1208.
107. Wrighton N.C., Farrell F.X., Chang R., Kashyap A.K., Barbone F.P., Mulcahy L.S. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273:458-464.
108. Yeh P., Landais D., Lemaitre M., et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA 1992, 89:1904-1908.